# Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

> **NCT03233347** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Academic and Community Cancer Research United** · enrollment: 82 (estimated)

## Conditions studied

- Ann Arbor Stage I Hodgkin Lymphoma
- Ann Arbor Stage IA Hodgkin Lymphoma
- Ann Arbor Stage IB Hodgkin Lymphoma
- Ann Arbor Stage II Hodgkin Lymphoma
- Ann Arbor Stage IIA Hodgkin Lymphoma
- Ann Arbor Stage IIB Hodgkin Lymphoma
- Classic Hodgkin Lymphoma

## Interventions

- **DRUG:** Brentuximab Vedotin
- **DRUG:** Dacarbazine
- **DRUG:** Doxorubicin
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Nivolumab
- **DRUG:** Vinblastine

## Key facts

- **NCT ID:** NCT03233347
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-10-13
- **Primary completion:** 2025-07-01
- **Final completion:** 2026-07-08
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2025-10-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03233347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03233347, "Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03233347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*